Targeted therapy for NSCLC: ALK inhibition

Rachel Pearson, Jill M. Kolesar

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Purpose: The purpose of this review article is to describe the emerging data of ALK receptor tyrosine kinaase inhibitors in ALK mutation positive NSCLC.Summary: ALK mutations have been identified in approximately 2.4-13% of patients with NSCLC, occurring more frequently in adenocarcinomas and never and light smokers. Crizotinib is an oral ATP-competitive selective inhibitor of the ALK and MET tyrosine kinases that inhibits tyrosine phosphorylation of activated ALK at nanomolar concentrations. A phase II study demonstrated an overall response rate of 57% (95% CI, 46 to 68), with the most common toxicity grade I fatigue and visual disturbances. Elevations in lever function tests were also reported.Conclusion: The ALK receptor tyrosine kinase inhibitor crizotinib may be an effective therapy in ALK mutated NSCLC and is currently being compared to standard chemotherapy for advanced or metastatic NSCLC.

Original languageEnglish
Pages (from-to)271-274
Number of pages4
JournalJournal of Oncology Pharmacy Practice
Issue number2
StatePublished - Jun 2012


  • ALK mutation
  • Non-small cell lung cancer
  • crizotinib

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Targeted therapy for NSCLC: ALK inhibition'. Together they form a unique fingerprint.

Cite this